Omicron-specific Sinopharm, Sinovac COVID vaccine candidates cleared for clinical trial | Reuters
COVID-19 vaccine candidates developed by a Sinopharm subsidiary and Sinovac Biotech to target the Omicron variant were approved for clinical trials in Hong Kong, the companies said on Saturday.